Compare Danaher Corporation (DHR) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Marqeta Inc — how do they compare? Danaher Corporation trades at $204.64 (market cap $145.83B), while Marqeta Inc trades at $15.46 (market cap $1.62B). The key difference: Danaher Corporation is far larger — about 90× Marqeta Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| DHR | MQ | |
|---|---|---|
Market Cap | $145.83B | $1.62B |
Sector | Health | Technology |
52-Week High | $242.05 | $26.00 |
52-Week Low | $161.91 | $15.04 |
Enterprise Value | $168.04B | $935.36M |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Marqeta (MQ) trades at $15.6, down 2.26% on the day, with a bearish technical outlook and mixed fundamentals. The stock recently underwent a 4:1 reverse split and shows improving revenue trends, though profitability remains thin. Recent news highlights partnerships with Google and Riskified to expand product offerings and reduce fraud.
The outlook is cautiously optimistic due to revenue growth and strategic expansions, but high valuation ratios and inconsistent earnings pose risks. Analyst consensus is a Buy with a $19 price target, suggesting potential upside if execution improves and margins expand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
